DT产业研究院 |10大链主企业 本文将对 生物制造产业10大链主企业即 凯赛生物、华恒生物、华东医药、梅花生物、川宁生物、华熙生物、富祥药业、朗坤科技、嘉必优、微构工场 基 本情况、主营构成、在研项目、发展策略等概况 进行梳理，以供参考。 01 凯赛生物（688065） 凯赛生物，首次突破30亿！ 1 、基本情况 作为生物基行业盛会风向标， #第11届生物基大会暨展览 （Bio-based 2026）将于5月20-22日在上海盛大举办。 聚焦生物基化学品和材料、应用上下游 ，囊括 " 11 大主题论坛 + 7大同期活动 + 1000 个新品展示 +DT新叶奖评选&颁奖 "同期活动。生物制造领域 微构工场、聚维元创、中科国生、利夫生物、道生生物、华澄生 物、 博辉合生等企业 已加盟参与，诚邀生物制造行业朋友们参与合作交流。 凯赛生物成立于 2000 年，2020 年 8 月登陆上交所科创板。公司是一家以合成生物学等学科为基础，利用生物制造技术，从事新型生物基材料的研发、 生产及销售的高新技术企业，经过多年发展，公司已成为全球领先的利用生物制造规模化生产新材料的企业之一。 公司主营新型生物基材料的研发、生产及销 ...

Core Viewpoint - Nestlé has initiated a precautionary recall of multiple batches of infant formula due to potential contamination of arachidonic acid (ARA) from suppliers with cereulide, a toxin produced by Bacillus cereus [2] Group 1: Company Responses - China Feihe stated that its ARA raw materials are not affected by any issues related to Bacillus cereus toxins and are safe for consumption [2] - Feihe emphasized that it uses powdered ARA as a raw material, which is different from the liquid ARA used by the foreign company involved in the recall [2] - The company adheres to internal quality standards that are stricter than EU standards, ensuring that all core raw materials undergo rigorous testing for microbial contamination, including Bacillus cereus, before production [2]

Core Viewpoint - Nestlé Group has expanded its recall of potentially contaminated infant formula to 50 countries due to the presence of a toxic substance, cereulide, which may cause digestive issues [1] Group 1: Recall Details - The recall affects major markets in Latin America, Asia, Africa, and the Middle East, including Brazil, Chile, China, Egypt, Qatar, Saudi Arabia, and the UAE, with at least 27 European countries also involved [1] - Nestlé China initiated a voluntary recall of all affected imported infant formula sold through cross-border e-commerce channels in mainland China [1] Group 2: Supplier and Contamination Issues - The contamination is linked to a specific raw material supplied by a global supplier, which contains cereulide, a toxin produced by Bacillus cereus [1] - The contaminated raw material is identified as an oil rich in Arachidonic Acid (ARA), a critical component in infant formula [2] Group 3: Industry Responses - DSM-Firmenich stated that the problematic ARA raw material was not supplied by them and is working to meet the increased demand for ARA [2] - Runke Bio confirmed that their products are not involved in the contamination issue and maintain strict quality control [2] - A2 Milk Company has not publicly responded yet but is in contact with testing agencies for product testing [3] - FrieslandCampina assured that their products are safe and not sourced from the implicated supplier [3] - Danone confirmed that their infant formula products do not use ARA from the affected supplier and adhere to high safety standards [3] - Yili Group stated that their ARA raw material is different from that of the recalled products and confirmed its safety [4]

Core Viewpoint - Nestlé Group has expanded its recall of potentially contaminated infant formula to 50 countries due to the presence of a toxic substance, prompting regulatory scrutiny in China [1][3]. Group 1: Recall Details - The recall affects major markets in Latin America, Asia, Africa, and the Middle East, including Brazil, Chile, China, Egypt, Qatar, Saudi Arabia, and the UAE, with at least 27 European countries also involved [3]. - The contaminated products are linked to a specific ingredient that may contain cereulide, a toxin from Bacillus cereus, which can cause gastrointestinal issues [3]. Group 2: Supplier Information - The contaminated ingredient is a type of oil rich in Arachidonic Acid (ARA), essential for infant brain and nervous system development [4]. - Nestlé has not disclosed the name of the supplier but referred to it as a "leading global supplier" [4]. - DSM-Firmenich confirmed that the problematic ARA was not supplied by them and is working to meet increased demand for ARA [4]. - Runke Bio stated that their products are not related to the contamination and have strict quality controls in place [4]. Group 3: Market Reactions - Companies like Feihe and Danone have assured that their products do not use the contaminated ARA and adhere to high safety standards [5][6]. - Feihe emphasized that their ARA is different from that used in the recalled products and confirmed no contamination issues [6]. - The stock of Jabiou, a listed company, dropped by 11.91% following the news, marking a nine-month low [5].

Group 1 - Jia Bi You Biotechnology (Wuhan) Co., Ltd. (stock code 688089.SH) is involved in Nestlé's global preventive recall of infant formula due to quality risks associated with ARA supplied by the company, leading to a stock price drop of over 13% [2] - Nestlé announced a recall of certain batches of infant formula in 31 countries, including China, due to the detection of Cereulide in ARA oil, which is produced by Bacillus cereus and can cause foodborne illness [2] - The affected products in China include four brands: Lidojing, Platinum Neng'en, Shuyi Neng'en, and Wyeth's Shaner Children's Growth Formula, totaling 30 batches, while other Nestlé products are not impacted by the recall [2] Group 2 - ARA (Arachidonic Acid) is a widely used Omega-6 polyunsaturated fatty acid in infant formula and dietary supplements, drawing significant consumer attention due to the incident [3] - Major ARA producers include DSM, Jia Bi You, and Runke Biotechnology, but Nestlé did not disclose the specific supplier involved in the issue [3] - Jia Bi You reported an ARA business revenue of 390 million yuan for 2024, a year-on-year increase of 29.2%, indicating that ARA is a core business for the company [3]

Core Viewpoint - The incident involving the recall of infant formula by Nestlé due to quality concerns related to ARA supplied by Jia Bi You has led to a significant drop in the company's stock price, highlighting potential risks in the supply chain and consumer confidence [1][2]. Group 1: Company Impact - Jia Bi You Biotechnology (Wuhan) Co., Ltd. has seen its stock price drop over 13% following the announcement of the recall by Nestlé [1]. - The company has stated that it has sent its products for testing and will release an announcement once the results are available [2]. - Jia Bi You's ARA business revenue for 2024 is projected to be 390 million yuan, reflecting a year-on-year growth of 29.2%, indicating that ARA is a core business for the company [2]. Group 2: Industry Context - The recall involves ARA, a widely used Omega-6 fatty acid in infant formula, which has raised consumer concerns in China [2]. - Major producers of ARA include companies like DSM, Jia Bi You, and Runke Biotechnology, with Nestlé not disclosing the specific supplier involved in the issue [2]. - Some dairy companies have distanced themselves from the incident, stating they do not use the implicated ARA raw materials, while others are monitoring the situation closely [2][3].

Core Insights - The article highlights the significant transformation in the industrial sector driven by biotechnology, emphasizing its role in achieving sustainable growth and meeting carbon neutrality goals [1][2][3] - The Chinese government has officially included biomanufacturing in its national strategy, indicating a strong commitment to advancing this sector through unprecedented measures and a national framework [1][10] - The biomanufacturing industry is projected to capture one-third of the global manufacturing output by the end of the century, creating a market worth approximately $30 trillion [4] Industry Overview - Biomanufacturing is transitioning traditional industries from high-energy, high-emission chemical processes to low-energy, low-pollution biological processes, which is essential for sustainable development [2][12] - The industry is gaining momentum globally due to its economic advantages, mild reaction conditions, and renewable raw materials, leading to a new industrial revolution [3] Government Initiatives - The Ministry of Industry and Information Technology (MIIT) has initiated the selection of "biomanufacturing landmark products" and "biomanufacturing pilot platforms," reflecting the strategic intent to identify and cultivate leading industry examples [5][10] - The MIIT's focus on key areas such as biomanufacturing, integrated circuits, and advanced materials aims to achieve decisive breakthroughs in core technologies [13] Company Spotlight: Jia Bi You - Jia Bi You has emerged as a focal point in the industry, successfully developing 2'-fucosyllactose (2'-FL), a human milk oligosaccharide with significant immune-regulating properties, which has been recognized as a landmark product by the MIIT [7][10] - The company has also been included in the first batch of biomanufacturing pilot capacity construction platforms and high-performance bioreactor innovation tasks, showcasing its advanced technology and market potential [8][9] Technological Advancements - Jia Bi You integrates artificial intelligence with synthetic biology to create an intelligent research and development platform, enhancing its capabilities in enzyme design and microbial strain development [18][37] - The company has developed a comprehensive biomanufacturing platform that includes advanced fermentation systems and real-time monitoring technologies, significantly improving production efficiency and product quality [18][21] Market Position and Growth - Jia Bi You has established itself as a leader in the biomanufacturing sector, with a diverse product portfolio that includes ARA, DHA, and various high-value nutrients, positioning itself to capture significant market opportunities [27][36] - The company has successfully penetrated international markets, collaborating with major global players and obtaining necessary certifications for its products, thereby expanding its global footprint [41][42] Future Prospects - The biomanufacturing sector is expected to experience rapid growth, driven by government support and technological innovation, with Jia Bi You poised to play a pivotal role in this transformation [45][46] - The establishment of innovation centers and collaborative initiatives in regions like Hubei is expected to enhance the overall competitiveness of the biomanufacturing industry in China [29][34]

Macro Strategy - The September FOMC meeting resulted in a 25bps rate cut, with guidance indicating two more cuts within the year and an additional cut next year, which is more hawkish than market expectations [1][17] - Powell's statements on employment and inflation were consistent with the August Jackson Hole meeting, lacking significant dovish information, leading to volatile movements in major asset classes [1][17] - The focus is shifting towards the independence of the Federal Reserve, with potential political pressures influencing future rate cuts and increasing dollar credit risks [1][17] Fixed Income Market - The convertible bond market experienced fluctuations, with high-priced bonds outperforming mid and low-priced ones, indicating a highly structured opportunity landscape driven by the current equity market [2][19] - The China convertible bond index has risen over 30% since August 2024, with a corresponding increase in the premium rate, suggesting a potential upward shift in the index amid improving corporate performance and increased refinancing needs in the tech sector [2][19] - The issuance of green bonds saw a significant increase, with 23 new bonds issued totaling approximately 20.052 billion yuan, reflecting a growing market interest [4][22] Industry Insights - In the semiconductor equipment sector, domestic equipment manufacturers are expected to benefit from the development of domestic computing power chips, with specific companies recommended for investment [12] - The oil service equipment industry is poised to benefit from Saudi Aramco's plans to initiate 85 major projects over three years, with specific companies highlighted for their strong growth potential [13] - Hikvision is positioned as a global leader in the security industry, expanding its digital transformation capabilities through innovative business segments, including industrial IoT and smart logistics [14][15]

Investment Rating - The report assigns a "Buy" rating for the company, marking its first coverage [1]. Core Views - The company has established a strong market position in the production of Arachidonic Acid (ARA) and Docosahexaenoic Acid (DHA), with significant growth potential driven by domestic and international demand [8][13]. - The company is expected to benefit from the expiration of patents held by competitors, allowing for increased market share and revenue growth [8][47]. - The financial forecasts indicate robust revenue and profit growth, with a projected revenue increase from 7.00 billion yuan in 2025 to 9.43 billion yuan in 2027, and net profit rising from 1.76 billion yuan to 2.55 billion yuan in the same period [1][8]. Summary by Sections 1. Company Overview - Founded in 2004, the company has pioneered the industrialization of ARA, DHA, and other products, with applications in human nutrition, animal nutrition, and personal care [8][13]. - The company has established long-term partnerships with global nutrition and dairy companies, exporting products to over 30 countries [8][13]. 2. Market Position and Growth - The company holds a market share of 13.5% globally and over 50% domestically in the ARA sector as of 2021, with expectations for further growth due to patent expirations of competitors [47]. - The domestic ARA market has shown a CAGR of 9.85% from 2015 to 2021, driven by rising disposable incomes and regulatory changes [46]. 3. Financial Performance - Revenue is projected to grow from 443.80 million yuan in 2023 to 942.93 million yuan by 2027, with a CAGR of 25.19% from 2023 to 2024 [1]. - Net profit is expected to increase from 91.37 million yuan in 2023 to 255.02 million yuan by 2027, reflecting a strong CAGR of 41.95% in 2024 [1]. 4. Product Segmentation - ARA is projected to account for approximately 70.2% of revenue in 2024, while DHA is expected to contribute 19.6% [15][26]. - The company is diversifying its product offerings, including SA and β-carotene, to enhance its market presence [15][13]. 5. Strategic Initiatives - The company is focusing on expanding its international market presence, particularly in light of the expiration of patents held by competitors, which will allow for competitive pricing and increased market penetration [8][47]. - The strategic direction emphasizes a dual focus on human nutrition and animal nutrition, with ongoing investments in product development and market expansion [8][13].

Core Viewpoint - The report highlights the financial performance and operational developments of Cabio Biotech (Wuhan) Co., Ltd. for the first half of 2025, showcasing significant growth in revenue and profit, alongside advancements in product offerings and market expansion strategies [1][3]. Company Overview and Financial Indicators - Cabio Biotech is a leading player in the synthetic biology sector, focusing on high-quality nutrient products and innovative solutions for the global nutrition and health market [4]. - The company reported a revenue of approximately 306.73 million yuan, representing a 17.60% increase compared to the same period last year [3]. - The total profit reached approximately 123.16 million yuan, marking a 57.82% increase year-on-year [3]. - The net profit attributable to shareholders was approximately 107.95 million yuan, up 59.01% from the previous year [3]. - The company's total assets increased by 12.31% to approximately 1.84 billion yuan, while net assets rose by 7.64% to approximately 1.63 billion yuan [3]. Main Business and Industry Situation - The company utilizes synthetic biology as a foundational technology to produce essential fatty acids and other bioactive compounds, which are widely used in infant formula, health foods, and personal care products [4][6]. - Key products include ARA (Arachidonic Acid), DHA (Docosahexaenoic Acid), and various oligosaccharides, which are essential for infant development and health [4][6]. - The company has established three production bases that meet international standards and has a comprehensive supply chain covering over 30 countries [4][6]. Market Trends and Opportunities - The Chinese government has implemented policies to encourage childbirth, which is expected to boost the maternal and infant consumption market, positively impacting the demand for ARA and DHA products [7]. - The global Omega-3 market is projected to grow significantly, with a focus on high-purity DHA products, driven by increasing health awareness and aging populations [8][10]. - The company is positioned to benefit from the growing trend of replacing fish oil with algae-derived DHA in various applications, including functional foods and clinical nutrition [10][11]. Technological Advancements and Competitive Edge - Cabio Biotech has developed a robust technological platform that integrates various capabilities in synthetic biology, enhancing its product development and production efficiency [14][16]. - The company has achieved several certifications, including FDA GRAS and EU Novel Food, ensuring the quality and safety of its products [15][16]. - Continuous investment in automation and smart manufacturing systems has improved production efficiency and product quality, solidifying the company's competitive position in the market [16][17].